Alliance Pharmaceuticals

Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB
Telephone: +44 (0)1249 466 966
Fax: +44 (0)1249 466 977
WWW: http://www.alliancepharma.co.uk
Medical Information e-mail: medinfo@alliancepharma.co.uk


Summary of Product Characteristics last updated on the eMC: 15/08/2011
SPC Anbesol Liquid


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Anbesol Liquid


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Lidocaine hydrochloride Ph Eur

0.9%w/w

Chlorocresol Ph Eur

0.1%w/w

Cetylpyridinium chloride Ph Eur

0.02%w/w


Go to top of the page
3. PHARMACEUTICAL FORM

Liquid for oral administration


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation and teething.


Go to top of the page
4.2 Posology and method of administration

Adults, the elderly and children: Apply undiluted to the affected area with the fingertip. Two applications immediately will normally be sufficient to obtain pain relief. Use up to 8 times a day.

Babies teething: One application only. Do not repeat for at least half an hour. Use up to 8 times a day.


Go to top of the page
4.3 Contraindications

Patients with known history of hypersensitivity or allergic type reactions to any of the constituents of the product.


Go to top of the page
4.4 Special warnings and precautions for use

If symptoms persist for more than 7 days consult your doctor or dentist. For babies teething, do not repeat for at least half an hour.

Keep all medicines out of the reach of children.

Do not exceed the stated dose.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

No special precautions required.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

There have been reports of non-specific ulceration following oral cetylpyridinium chloride therapy.


Go to top of the page
4.9 Overdose

Ingestion of the complete contents of the marketed pack would not be expected to cause any adverse effects.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Lidocaine hydrochloride

Absorption and fate: lidocaine is readily absorbed from mucous membranes and through damaged skin. Lidocaine undergoes first-pass metabolism in the liver and about 90% is dealkylated to form monoethylglycinexylidide and glycinexylidide. Further metabolism occurs and the metabolites are excreted in the urine with less than 10% as unchanged lidocaine.

Chlorocresol

Absorption: there is no significant absorption of chlorocresol through the skin or mucous.

Cetylpyridinium chloride

Absorption: there is no significant absorption of cetylpyridinium chloride through the skin or mucous membranes.


Go to top of the page
5.2 Pharmacokinetic properties

Lidocaine hydrochloride

White crystalline powder soluble in water and alcohol.

Mechanism of action/effect: lidocaine is a local anaesthetic of the amide type, which acts by reversible inhibition of nerve impulse generation and transmission.

Chlorocresol

Colourless crystals or a white crystalline powder slightly soluble in water and alcohol.

Chlorocresol has a disinfectant action.

Cetylpyridinium chloride

A white unctuous powder soluble in water and alcohol.

Mechanism of action/effect: cetylpyridinium chloride has a disinfectant action.


Go to top of the page
5.3 Preclinical safety data

None stated


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Alcohol 96%, menthol, glycerin, caramel colour*, purified water

*contains colorants E110, E104, E123, E142


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

36 months unopened


Go to top of the page
6.4 Special precautions for storage

Store at a temperature not exceeding 25°C


Go to top of the page
6.5 Nature and contents of container

6.5ml, 15ml: glass bottles


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Alliance Pharmaceuticals Limited

Avonbridge House

Bath Road

Chippenham

Wiltshire

SN15 2BB

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 16853/0128


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

30/07/1998


Go to top of the page
10. DATE OF REVISION OF THE TEXT

21st July 2011



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/4437/SPC/


Active Ingredients/Generics

 
   lidocaine hydrochloride
   chlorocresol
   cetylpyridinium chloride